中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 9
Sep.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(9): 1908-1912

Safe platelet threshold in patients undergoing endoscopic variceal ligation and cyanoacrylate injection due to esophagogastric variceal bleeding： Consensus and challenges

DOI: 10.12449/JCH250929
  • 1.

    Department of Gastroenterology Guangzhou Eighth People’s Hospital，Guangzhou Medical University Guangzhou 510440 China

  • 2.

    Department of Severe Liver Disease Guangzhou Eighth People’sHospital，Guangzhou Medical University Guangzhou 510440 China

  • 3.

    Department of Neurology，Guangzhou Eighth People’s Hospital，Guangzhou Medical University Guangzhou 510440 China

  • 4.

    Department of Gastroenterology，Guangzhou First People’s Hospital，Guangzhou 510180，China

Research funding:

Medical Research Foundation of Guangdong Province (A2022491)

More Information
  • Corresponding author: HUANG Chunming， gz8hhcm@163.com （ORCID： 0009-0009-9272-5802）
  • Received Date: 2025-01-19
  • Accepted Date: 2025-02-12
  • Published Date: 2025-09-25
    Abstract
  • Esophagogastric variceal bleeding is a common complication and the leading cause of death in advanced liver cirrhosis， and endoscopic variceal ligation （EVL） and endoscopic cyanoacrylate injection （ECI） are commonly used treatment strategies. Thrombocytopenia is one of the most common hematological complications in liver cirrhosis， and patients with severe thrombocytopenia have the potential risk of bleeding， which may affect treatment decision-making by clinicians and endoscopists. This article reviews the evolution of guidelines and clinical research advances regarding EVL/ECI in China and globally， in order to provide a basis for decision making among clinicians.

     

    • FullText(HTML)
  • loading
    • References(38)
  • [1]
    Chinese Society of Hepatology, Chinese Society of Gastroenterology, and Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2023, 39( 3): 527- 538.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2023, 39( 3): 527- 538.
    [2]
    Endoscopic Diagnosis and Treatment of Esophagogastric Varices group of Chinese Society of Digestive Endoscopology. Chinese expert consensus on endoscopic cyanoacrylate injection for gastrointestinal varices with portal hypertension induced by liver cirrhosis(2022, Changsha)[J]. Chin J Dig Endosc, 2023, 40( 1): 12- 23. DOI: 10.3760/cma.j.cn321463-20221016-00530.

    中华医学会消化内镜学分会食管胃静脉曲张内镜诊断与治疗学组. 肝硬化门静脉高压消化道静脉曲张内镜下组织胶注射治疗专家共识(2022, 长沙)[J]. 中华消化内镜杂志, 2023, 40( 1): 12- 23. DOI: 10.3760/cma.j.cn321463-20221016-00530.
    [3]
    National Clinical Research Center for Infectious Diseases; Society of Hepatology, Beijing Medical Association; Translational Medicine Branch, Chinese Association of Gerontology and Geriatrics. Chinese expert consensus on clinical management of hepatopathy-related thrombocytopenia[J]. J Clin Hepatol, 2023, 39( 10): 2307- 2320. DOI: 10.3969/j.issn.1001-5256.2023.10.007.

    国家感染性疾病临床医学研究中心, 北京医学会肝病学分会, 中国老年学和老年医学学会转化医学分会. 肝病相关血小板减少症临床管理中国专家共识[J]. 临床肝胆病杂志, 2023, 39( 10): 2307- 2320. DOI: 10.3969/j.issn.1001-5256.2023.10.007.
    [4]
    Liver Fibrosis, Cirrhosis and Portal Hypertension Group, Chinese Society of Hepatology, Chinese Medical Association. Concise guidelines for the clinical management of thrombocytopenia in cirrhosis[J]. Chin J Hepatol, 2024, 32( 10): 865- 871. DOI: 10.3760/cma.j.cn501113-20240806-00361.

    中华医学会肝病学分会肝纤维化、肝硬化及门静脉高压学组. 肝硬化血小板减少症临床管理实用指南[J]. 中华肝脏病杂志, 2024, 32( 10): 865- 871. DOI: 10.3760/cma.j.cn501113-20240806-00361.
    [5]
    ASGE Standards of Practice Committee, PASHA SF, ACOSTA R, et al. Routine laboratory testing before endoscopic procedures[J]. Gastrointest Endosc, 2014, 80( 1): 28- 33. DOI: 10.1016/j.gie.2014.01.019.
    [6]
    National Clinical Guideline Centre(UK). Blood Transfusion[M]. London: National Institute for Health and Care Excellence(NICE), 2015.
    [7]
    GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2017, 65( 1): 310- 335. DOI: 10.1002/hep.28906.
    [8]
    ANDRIULLI A, TRIPODI A, ANGELI P, et al. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference[J]. Dig Liver Dis, 2016, 48( 5): 455- 467. DOI: 10.1016/j.dld.2016.02.008.
    [9]
    REIBERGER T, PÜSPÖK A, SCHODER M, et al. Austrian consensus guidelines on the management and treatment of portal hypertension(Billroth Ⅲ)[J]. Wien Klin Wochenschr, 2017, 129( Suppl 3): 135- 158. DOI: 10.1007/s00508-017-1262-3.
    [10]
    O’LEARY JG, GREENBERG CS, PATTON HM, et al. AGA clinical practice update: Coagulation in cirrhosis[J]. Gastroenterology, 2019, 157( 1): 34- 43. e 1. DOI: 10.1053/j.gastro.2019.03.070.
    [11]
    NORTHUP PG, GARCIA-PAGAN JC, GARCIA-TSAO G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2021, 73( 1): 366- 413. DOI: 10.1002/hep.31646.
    [12]
    SIMONETTO DA, SINGAL AK, GARCIA-TSAO G, et al. ACG clinical guideline: Disorders of the hepatic and mesenteric circulation[J]. Am J Gastroenterol, 2020, 115( 1): 18- 40. DOI: 10.14309/ajg.000000000000-0486.
    [13]
    ROBERTS LN, LISMAN T, STANWORTH S, et al. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH[J]. J Thromb Haemost, 2022, 20( 1): 39- 47. DOI: 10.1111/jth.15562.
    [14]
    O’SHEA RS, DAVITKOV P, KO CW, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis[J]. Gastroenterology, 2021, 161( 5): 1615- 1627. e 1. DOI: 10.1053/j.gastro.2021.08.015.
    [15]
    European Association for the Study of the Liver. EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis[J]. J Hepatol, 2022, 76( 5): 1151- 1184. DOI: 10.1016/j.jhep.2021.09.003.
    [16]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
    [17]
    RIESCHER-TUCZKIEWICZ A, CALDWELL SH, KAMATH PS, et al. Expert opinion on bleeding risk from invasive procedures in cirrhosis[J]. JHEP Rep, 2023, 6( 3): 100986. DOI: 10.1016/j.jhepr.2023.100986.
    [18]
    BIOLATO M, VITALE F, GALASSO T, et al. Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines[J]. World J Gastrointest Surg, 2023, 15( 2): 127- 141. DOI: 10.4240/wjgs.v15.i2.127.
    [19]
    GIRI S, SUNDARAM S, JEARTH V, et al. Predictors of early bleeding after endoscopic variceal ligation for esophageal varices: A systematic review and meta-analysis[J]. Clin Exp Hepatol, 2022, 8( 4): 267- 277. DOI: 10.5114/ceh.2022.123096.
    [20]
    VIEIRA da ROCHA EC, D’AMICO EA, CALDWELL SH, et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation[J]. Clin Gastroenterol Hepatol, 2009, 7( 9): 988- 993. DOI: 10.1016/j.cgh.2009.04.019.
    [21]
    de OLIVEIRA SOUZA E, ÉA D’AMICO, FLORES da ROCHA TR, et al. Preservation of platelet function in patients with cirrhosis and thrombocytopenia undergoing esophageal variceal ligation[J]. Hepatobiliary Pancreat Dis Int, 2020, 19( 6): 555- 560. DOI: 10.1016/j.hbpd.2019.12.009.
    [22]
    PFISTERER N, SCHWARZ M, JACHS M, et al. Endoscopic band ligation is safe despite low platelet count and high INR[J]. Hepatol Int, 2023, 17( 5): 1205- 1214. DOI: 10.1007/s12072-023-10515-y.
    [23]
    di MARTINO V, SIMONE F, GRASSO M, et al. Child-pugh class and not thrombocytopenia impacts the risk of complications of endoscopic band ligation in patients with cirrhosis and high risk varices[J]. J Pers Med, 2023, 13( 5): 764. DOI: 10.3390/jpm13050764.
    [24]
    DROLZ A, SCHRAMM C, SEIZ O, et al. Risk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis[J]. Endoscopy, 2021, 53( 3): 226- 234. DOI: 10.1055/a-1214-5355.
    [25]
    HU YH, ZHOU M, LIU DL, et al. Risk factors for rebleeding after endoscopic injection of cyanoacrylate glue for gastric varices: A systematic review and meta-analysis[J]. Dig Dis Sci, 2024, 69( 8): 2890- 2903. DOI: 10.1007/s10620-024-08482-x.
    [26]
    SOLVES AP. Platelet transfusion: And update on challenges and outcomes[J]. J Blood Med, 2020, 11: 19- 26. DOI: 10.2147/JBM.S234374.
    [27]
    LISMAN T, BONGERS TN, ADELMEIJER J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity[J]. Hepatology, 2006, 44( 1): 53- 61. DOI: 10.1002/hep.21231.
    [28]
    NAPOLITANO G, IACOBELLIS A, MERLA A, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia[J]. Eur J Intern Med, 2017, 38: 79- 82. DOI: 10.1016/j.ejim.2016.11.007.
    [29]
    BLASI A, MACHLAB S, RISCO R, et al. A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation[J]. JHEP Rep, 2021, 3( 6): 100363. DOI: 10.1016/j.jhepr.2021.100363.
    [30]
    SLICHTER SJ. Evidence-based platelet transfusion guidelines[J]. Hematology Am Soc Hematol Educ Program, 2007: 172- 178. DOI: 10.1182/asheducation-2007.1.172.
    [31]
    BISWAS S, VAISHNAV M, PATHAK P, et al. Effect of thrombocytopenia and platelet transfusion on outcomes of acute variceal bleeding in patients with chronic liver disease[J]. World J Hepatol, 2022, 14( 7): 1421- 1437. DOI: 10.4254/wjh.v14.i7.1421.
    [32]
    TERRAULT N, CHEN YC, IZUMI N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia[J]. Gastroenterology, 2018, 155( 3): 705- 718. DOI: 10.1053/j.gastro.2018.05.025.
    [33]
    ABDELA J. Current advance in thrombopoietin receptor agonists in the management of thrombocytopenia associated with chronic liver disease: Focus on avatrombopag[J]. Clin Med Insights Blood Disord, 2019, 12: 1179545 X 19875105. DOI: 10.1177/1179545X19875105.
    [34]
    QURESHI K, PATEL S, MEILLIER A. The use of thrombopoietin receptor agonists for correction of thrombocytopenia prior to elective procedures in chronic liver diseases: Review of current evidence[J]. Int J Hepatol, 2016, 2016: 1802932. DOI: 10.1155/2016/1802932.
    [35]
    FLISIAK R, ANTONOV K, DRASTICH P, et al. Practice guidelines of the central European hepatologic collaboration(CEHC) on the use of thrombopoietin receptor agonists in patients with chronic liver disease undergoing invasive procedures[J]. J Clin Med, 2021, 10( 22): 5419. DOI: 10.3390/jcm10225419.
    [36]
    HIDAKA H, KUROSAKI M, TANAKA H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures[J]. Clin Gastroenterol Hepatol, 2019, 17( 6): 1192- 1200. DOI: 10.1016/j.cgh.2018.11.047.
    [37]
    TRIPODI A, MANNUCCI PM. The coagulopathy of chronic liver disease[J]. N Engl J Med, 2011, 365( 2): 147- 156. DOI: 10.1056/NEJMra101-1170.
    [38]
    PATEL IJ, RAHIM S, DAVIDSON JC, et al. Society of interventional radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-part Ⅱ: Recommendations: Endorsed by the Canadian association for interventional radiology and the cardiovascular and interventional radiological society of Europe[J]. J Vasc Interv Radiol, 2019, 30( 8): 1168- 1184. e 1. DOI: 10.1016/j.jvir.2019.04.017.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (132) PDF downloads(15) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return